Ypsomed Holding AGXSWX:YPSN +1.91%91 EBITDA Margin % is 37.92% as of Mar. 2026, which is 59% above its 10-year median of 23.80. GuruFocus rates XSWX:YPSN with a GF Score™ of 91/100 and a GF Value™ of CHF397.52 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Ypsomed Holding AG ranks better than 98.04% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ypsomed Holding AG's EBITDA for the
six
months ended in Mar. 2026 was CHF139.7 Mil. Ypsomed Holding AG's Revenue for the
six
months ended in Mar. 2026 was CHF368.3 Mil. Therefore, Ypsomed Holding AG's EBITDA margin for the quarter that ended in Mar. 2026 was 37.92%.
Ypsomed Holding AG (XSWX:YPSN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ypsomed Holding AG EBITDA Margin % Related Terms
Ypsomed Holding AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:YPSN vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG (XSWX:YPSN) has a EBITDA Margin % of 37.92% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ypsomed Holding AG and its competitors. This is 59% above median its historical median of 23.80. Over the past decade, Ypsomed Holding AG's EBITDA Margin % has ranged from 15.58 to 44.65. According to the industry distribution chart, Ypsomed Holding AG ranks #16 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Ypsomed Holding AG's EBITDA Margin % too high?
Ypsomed Holding AG's current EBITDA Margin % of 37.92% is 59% above median its 10-year median of 23.80. Over the past 10 years, this metric has ranged from a low of 15.58 to a high of 44.65. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Ypsomed Holding AG's value of 37.92% is 407.3% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #16 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ypsomed Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #16 out of 816 companies for EBITDA Margin %. This places Ypsomed Holding AG in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Ypsomed Holding AG's value of 37.92% is 407.3% above this benchmark. Historically, Ypsomed Holding AG's own EBITDA Margin % has ranged from 15.58 to 44.65 over the past decade. While the company's 10-year median is 23.80 vs. the industry median of 7.48, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current EBITDA Margin % of 37.92% is 407.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current EBITDA Margin % is 37.92%, which is 59% above median its own 10-year median of 23.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF397.52, compared to a current price of CHF353.00 — trading 11.2% below its estimated fair value. The current EBITDA Margin % is 37.92%, which is 59% above median its 10-year median of 23.80 and 407.3% above the Medical Devices & Instruments industry median of 7.48. Ypsomed Holding AG's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current EBITDA Margin % is 37.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF353.00 is trading 11.2% below its estimated GF Value™ of CHF397.52.
GuruFocus considers Ypsomed Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:YPSN:
EBITDA Margin %: 37.92% (59% above median its 10-year median of 23.80)
GF Value™: CHF397.52 vs. price of CHF353.00 (11.2% below fair value)
Industry Position: 407.3% above the Medical Devices & Instruments median (#16 of 816)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
91GF Score
Get the complete analysis for XSWX:YPSN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
